Nebivolol hydrochloride Drug Asset Due Diligence Report 2026

This Nebivolol hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

152

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Nebivolol hydrochloride can convert its Small molecule drug profile and β1-adrenergic receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Nebivolol hydrochloride (query alias: nebivolol)
Modality / target	Small molecule drug; β1-adrenergic receptor; β1-adrenergic receptor antagonists
Highest global status	Approved
Originator	A.Menarini Industrie Farmaceutiche Riunite Srl
Active developers	A. Menarini China Holding Co., Ltd., A. Menarini Australia Pty Ltd., Allergan Sales LLC

The MCP disease footprint includes Chronic heart failure, Essential Hypertension, Hypertension. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07397481	Phase 4	Completed	40	Management of arterial hypertension
CTR20260928	Phase 3	进行中（招募中）	320	Not disclosed
NCT07233499	Phase 2	Recruiting	56	Measurement of Left ventricular ejection fraction by Echocardiography

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Differential Effects of Antihypertensive Drugs on Central Blood Pressure: A Randomized Comparison Between Nebivolol and Telmisartan

Not Applicable; n=98; evaluation: Negative. Reported fields: cSBP(12-week): Difference = 12.7(95.0% CI, 4.1 - 21.2), P-Value = 0.004; cSBP(12-week): Difference = 12.7(95.0% CI, 4.1 - 21.2), P-Value = 0.004

Ambulatory 24-Hour Cardiac Oxygen Consumption and Blood Pressure-Heart Rate Variability: Effects of Nebivolol and Valsartan Alone and in Combination

Phase 3; n=26; evaluation: not stated. Reported fields: ACRPP: 24-hour Ambulatory Central Rate-pressure Product (Also Called TTI, CTTI)(Mean) = 2484 mmHg*beats/min (Standard Deviation, 368); ACRPP: 24-hour Ambulatory Central Rate-pressure Product (Also Called TTI, CTTI)(Mean) = 2531 mmHg*beats/min (Standard Deviation, 400); ACRPP: 24-hour Ambulatory Central Rate-pressure Product (Also Called TTI, CTTI)(Mean): P-Value = 0.05

Open-label, Multicenter, multinAtionaL, inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients - ARTEMISIA Study

Phase 4; n=266; evaluation: not stated. Reported fields: Primary Outcome: Change in Mean Sitting SBP(Mean) = -19.2 mmHg (Standard Deviation, 8.62); Primary Outcome: Change in Mean Sitting SBP(Mean): Mean difference pre vs post treatment = -19.2(95% CI, -26.0 to -14.0), P-Value = < 0.001; Primary Outcome: Change in Mean Sitting SBP(Mean): Mean difference pre vs post treatment = -19.2(95% CI, -26.0 to -14.0), P-Value = < 0.001

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Nebivolol hydrochloride addresses Chronic heart failure, Essential Hypertension, Hypertension. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2019-01-28	Kowa Pharmaceuticals and Allergan collaborate to promote nebivolol in the US market.	Approved	Financial terms not disclosed
2012-04-02	Forest Laboratories, Inc. Buys Blood Pressure Drug Bystolic From Johnson & Johnson's Janssen Pharmaceutica N.V. for $357 Million	Approved	US$357.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Nebivolol and amlodipine composition, preparation method therefor, and use thereof”. The milestone feed surfaced a patent-application signal described as “Nebivolol hydrochloride transdermal patch and preparation method thereof”. The milestone feed surfaced a patent-application signal described as “Formulation of fast dissolving films of nebivolol and its method of preparation thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO